Key Highlights

  • Net loss per share was USD 0.07 against an estimate of a USD 0.30 loss.
  • Revenue was USD 6.41 million against an estimate of USD 5.47 million.
  • Net loss was USD 1.97 million, compared with USD 5.40 million.
  • Cash and cash equivalents were USD 247 thousand at September 30, 2026.

Vivos Therapeutics Inc. (NASDAQ:VVOS) reported third quarter 2026 Revenue of USD 6.41 million, compared with USD 6.78 million in the prior-year quarter. Revenue was USD 6.41 million against an estimate of USD 5.47 million.

Basic and diluted net loss per share was USD 0.07, compared with USD 0.49, against an estimate of a USD 0.30 loss. The net loss was USD 1.97 million, compared with USD 5.40 million.

Third Quarter Results

Product revenue was USD 1.77 million, compared with USD 2.20 million, and service revenue was USD 4.64 million, compared with USD 4.59 million. Cost of sales was USD 3.10 million, compared with USD 2.85 million, and Gross Profit was USD 3.31 million, compared with USD 3.94 million.

General and administrative expense was USD 6.45 million, compared with USD 7.88 million, and sales and Marketing expense was USD 210 thousand, compared with USD 403 thousand. Depreciation and amortization was USD 550 thousand, compared with USD 384 thousand, and total operating expenses were USD 7.21 million, compared with USD 8.67 million.

The operating loss was USD 3.90 million, compared with USD 4.73 million. Other expense was USD 981 thousand, compared with USD 679 thousand, and other income was USD 2.91 million, compared with USD 13 thousand.

The net loss attributable to non-controlling interest was USD 26 thousand and the net loss attributable to stockholders was USD 1.95 million. Weighted average shares outstanding were 26,528,253, compared with 10,963,590.

Nine-Month Results

For the nine months ended September 30, 2026, revenue was USD 16.71 million, compared with USD 13.62 million, and gross profit was USD 9.33 million, compared with USD 7.55 million. General and administrative expense was USD 22.53 million, compared with USD 19.18 million.

The operating loss was USD 15.34 million, compared with USD 13.51 million, and the net loss was USD 15.25 million, compared with USD 14.28 million. Net loss per share was USD 0.77, compared with USD 1.49. Net cash used in Operating Activities was USD 12.33 million, compared with USD 11.45 million.

Balance Sheet and Going Concern Disclosure

Cash and cash equivalents were USD 247 thousand at September 30, 2026, compared with USD 2.03 million at December 31, 2025. Total Assets were USD 22.86 million, compared with USD 25.15 million, and total liabilities were USD 20.69 million, compared with USD 26.70 million.

Current liabilities were USD 16.16 million, compared with USD 18.08 million. The filing states that cash of approximately USD 0.2 million is not sufficient to fund operations over the next twelve months and discloses substantial doubt about the company's ability to continue as a going concern. It reports approximately USD 2.3 million of outstanding principal under a senior secured note due June 10, 2027.

Vivos Therapeutics Q3 2026 Earnings: Key Takeaways

Vivos Therapeutics reported third quarter 2026 revenue of USD 6.41 million and a net loss of USD 1.97 million. Cash and cash equivalents were USD 247 thousand at September 30, 2026.